Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
type: Dataset
description: International audience
issued: 2026-05-15T11:05:31.680533
language: en
modified: 2026-05-15T11:05:31.680539
contact point: Organization
  fn: CCSD
keyword: infoeu-reposemanticsarticle
keyword: journal-articles
keyword: mesh-adult
keyword: mesh-aged
keyword: mesh-angiogenesis-inhibitors
keyword: mesh-antibodies-monoclonal
keyword: mesh-antibodies-monoclonal-humanized
keyword: mesh-antineoplastic-combined-chemotherapy-protocols
keyword: mesh-carboplatin
keyword: mesh-cyclophosphamide
keyword: mesh-drug-administration-schedule
keyword: mesh-female
keyword: mesh-humans
keyword: mesh-intestinal-fistula
keyword: mesh-intestinal-perforation
keyword: mesh-middle-aged
keyword: mesh-neoplasms-glandular-and-epithelial
keyword: mesh-ovarian-neoplasms
keyword: mesh-paclitaxel
keyword: mesh-rectovaginal-fistula
keyword: mesh-retrospective-studies
keyword: mesh-taxoids
keyword: mesh-treatment-outcome
keyword: mesh-urinary-bladder-fistula
keyword: mesh-vascular-endothelial-growth-factor-a
keyword: mesh-vinblastine
keyword: sdvcanlife-sciences-q-biocancer
landing page: 0007-4551

Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study.
type: Distribution
format: HTML
issued: 2026-05-15T11:05:31.784357
modified: 2026-05-15T11:05:31.610506
access URL: https://hal.science/hal-00772144

test_moissonnage_selune
type: Agent